NASDAQ$CLMT
Calumet Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
CLMT reported Q3 2025, revenue of $1.08B, net income of $313.4M.
For Q3 2025, CLMT reported revenue of $1.08B, net income of $313.4M. Management discusses operating trends, liquidity, and strategic priorities as disclosed in the quarterly filing.
- Revenue $1.08B.
- Net income $313.4M.
- CLMT updated clinical, capital, or portfolio priorities in the filing.
Headline financials
Revenue & EPS history
Calumet Specialty Products · Revenue · Quarterly
$1.08B
Forward guidance
Management discusses CLMT's outlook, capital deployment, and key risks as disclosed in the earnings materials and periodic report.
Tailwinds
- CLMT cited progress on strategic priorities in the quarterly filing.
- Liquidity and balance sheet support continued operations and investment.
Headwinds
- Macro, competitive, and regulatory factors may affect near-term results.
- R&D, credit, or project timing can create quarter-to-quarter volatility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q3 2025
-4.3%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+6.6%
Avg return
30 days after
17%
1 / 6 earnings
Positive
+6.5%
Q1 2025
Best reaction
-10.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.4% | -9.3% | +1.5% | |
| Q4 2025 | -10.8% | -3.0% | +6.1% | |
| Q3 2025 | -1.6% | -3.0% | -0.9% | |
| Q2 2025 | -3.6% | -4.2% | +19.7% | |
| Q1 2025 | +6.5% | +11.4% | +14.9% | |
| Q3 2024 | -8.6% | -6.0% | -1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro